Highlights
IIA supported (ever)1 patentProfile claimed by owner
About
Liposome Delivery for Cancer Therapy
LipoMedix Pharmaceuticals is a privately held development-stage company focused on an innovative, safe, and effective cancer therapy based on liposome delivery. The companys lead product, Promitil, has demonstrated antitumor effects in tumor models that rival or outperform the effects of many standard forms of chemotherapy, such as cisplatin, irinotecan, gemcitabine, and doxorubicin, with less toxicity.
Identity
| Name | LipoMedix |
|---|---|
| Slug | lipomedix |
| Type / kind | startup |
| Crunchbase ID | lipomedix |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6sq7wKDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Giv'at Ram, Jerusalem, Israel |
Web & social
| Website | https://www.lipomedix.com |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
canceroncologybiopharmaceuticaldrug-deliverytargeted-therapychemotherapytherapeuticspharmaceuticalspharma-companies
Funding
| Total raised | $56K |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}